18580703. BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY simplified abstract (WISCONSIN ALUMNI RESEARCH FOUNDATION)
Contents
BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY
Organization Name
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventor(s)
Kenneth Craig Kent of Charlottesville VA (US)
Liang-Wang Guo of Madison WI (US)
Bowen Wang of Charlottesville VA (US)
Takuro Shirasu of Charlottesville VA (US)
Shaoqin Gong of Middleton WI (US)
BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY - A simplified explanation of the abstract
This abstract first appeared for US patent application 18580703 titled 'BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY
The disclosure pertains to nanoclusters with cores made of self-assembled unimolecular nanoparticles and biomimetic membrane coatings, along with methods of production and applications in treating and preventing restenosis. Some nanoclusters may include an anti-restenotic drug, while the nanoparticles' polymers can feature hydrophobic groups like phenylboronic esters. The biomimetic membrane can target damaged vascular sites, where reactive oxygen species cleave the hydrophobic groups, enhancing tissue penetration of the de-clustered nanoclusters and nanoparticles.
- Nanoclusters with self-assembled unimolecular nanoparticles and biomimetic membrane coatings
- Potential inclusion of anti-restenotic drugs in nanoclusters
- Polymers with hydrophobic groups like phenylboronic esters in nanoparticles
- Biomimetic membrane targeting damaged vascular sites
- Reactive oxygen species cleaving hydrophobic groups to enhance tissue penetration
- Potential Applications:**
The technology can be used in drug delivery systems for treating and preventing restenosis, particularly targeting damaged vascular sites effectively.
- Problems Solved:**
The technology addresses the challenge of enhancing tissue penetration of nanoparticles at damaged vascular sites, improving drug delivery efficiency.
- Benefits:**
Improved drug delivery to damaged vascular sites, enhanced treatment and prevention of restenosis, and increased effectiveness of anti-restenotic drugs.
- Commercial Applications:**
Title: Advanced Drug Delivery System for Restenosis Treatment This technology can be utilized in pharmaceutical companies for developing innovative drug delivery systems targeting restenosis, potentially leading to improved patient outcomes and market competitiveness.
- Prior Art:**
Researchers can explore prior studies on nanoclusters, biomimetic membranes, and drug delivery systems for cardiovascular diseases to understand the existing knowledge in this field.
- Frequently Updated Research:**
Stay updated on advancements in nanotechnology, drug delivery systems, and cardiovascular disease treatments to enhance the understanding and potential applications of this technology.
- Questions about Nanoclusters with Biomimetic Membrane Coatings:**
1. How do nanoclusters with biomimetic membrane coatings improve drug delivery efficiency? 2. What are the key advantages of using polymers with hydrophobic groups in nanoparticles for targeting damaged vascular sites?
Original Abstract Submitted
In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.
